Winrevair (sotatercept-csrk), when added to standard of care, reduced clinical worsening events by 76% in adults recently diagnosed with pulmonary arterial hypertension (PAH). That’s according to now-published data from the Phase 3 HYPERION (NCT04811092) clinical trial, which evaluated Merck‘s approved therapy against a placebo in patients who were within one year of their PAH diagnosis. Patients in both […] The post Winrevair reduces clinical worsening events in PAH: Trial data appe...
